Crohn's disease-occurrence, course and prognosis: An epidemiologic cohort-study

Danish Medical Bulletin

Volumn 44, Issue 3, 1997, Pages 287-302

  Munkholm, Pia ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ACETYLSALICYLIC ACID; FOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; SALAZOSULFAPYRIDINE;

CANCER PREVENTION; CLINICAL TRIAL; CROHN DISEASE; DENMARK; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; GENETIC MARKER; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; INTESTINE MUCOSA PERMEABILITY; META ANALYSIS; PROGNOSIS; REVIEW;

COHORT STUDIES; CROHN DISEASE; DENMARK; HUMANS; INCIDENCE; PROGNOSIS;

EID: 0030841756     PISSN: 09078916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (203)

1. Munkholm P, Langholz E, Haagen Nielsen O, Kreiner S, Binder V. Incidence and prevalence of Crohn's disease in the County of Copenhagen, 1962-87: A sixfold increase in incidence. Scand J Gastroenterol 1992; 27: 609-14.
2. Munkholm P, Langholz E, Hollander D, Thornberg K, Orholm M, Katz K.D., Binder V. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 1994; 35: 68-72.
3. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105: 1716-23.
4. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706.
5. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994; 35: 360-62.
6. 51Cr-labeledethylenediaminetetraacetic acid in patients with Crohn's disease and their healthy relatives. Scand J Gastroenterol 1989; 24: 993-8.
7. Alexander-Williams J. Surgical aspects of inflammatory bowel disease. Scand J Gastroenterol 1990, 25(suppl 172): 39-42.
8. Allan A, Andrews H, Hilton CJ, Keighley MRB, Allan RN, Alexander-Williams J. Segmental colonic resection is an appropriate operation for short skip lesions due to Crohn's disease in the colon. World J Surg 1989; 13: 611-6.
9. Allan RN, Pease P, Ibbotson JP. Clustering of Crohn's disease in a cotswold village. Quart J Med 1986; 229: 473-78.
10. Axon ATR. Carcinogenesis in ulcerative colitis: Is surveillance worthwhile? Can J Gastroenterol 1990; 4: 397-9.
11. Bennett A, Del Tacca M, Stamford IF, Zebro T. Prostaglandins from tumours of human large bowel. Br J Cancer 1977; 35: 881-4.
12. Beeken WL. Transmissible agents in inflammatory bowel disease. Medical Clinics of North America 1980; 64: 1021-35.
13. Bergman L, Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopynn®) after radical resection for Crohn's disease. Scand J Gastroenterol 1976; 11: 651-6.
14. Berkson J. Limitations of the application of fourfold table analysis to hospital data. Biomet Bull 1946; 2: 47-53.
15. Bernstein CN, Shanahan F, Weinstein WM. Are we telling the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343: 71-4.
16. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's Disease Activity Index. Gastroenterology 1979; 77: 439-44.
17. Binder V. A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa and cytologic picture of mucosal exudate in ulcerative colitis. Scand J Gastroenterol 1970; 5: 627-32.
18. Binder V, Both H, Hansen PK, Hendriksen C, Kreiner S, Torp-Pedersen K. Incidence and prevalence of ulcerative colitis and Crohn's disease in the county of Copenhagen 1962-1987. Gastroenterology 1982; 83: 563-8.
19. Binder V, Hendriksen C, Kreiner S. Prognosis in Crohn's disease -based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146-50.
20. Bishop YMM, Fienberg SF, Holland PW. Discrete multivariate analysis. Theory in practice. MIT Press, 1971: 257-79.
21. Bjarnason I, Levi S, Smethurst P, Menzies IS, Levi AJ. Vindaloo and you. Br Med J 1988; 297: 1629-31.
22. Bjarnason I, Williams P, So A, Zanelli GD, Levi AJ, Gumpel JM et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 1984; 1: 1171-4.
23. Björnsson S, Jóhannsson JH, Oddsson E. Inflammatory bowel disease in Iceland in 1980-1989: An epidemiological study. United European Gastroenterology Week Oslo 1994; A119 (Abstract).
24. Blackburn G, Hadfield G, Hunt AH. Regional ileitis. St Bart Hosp Rep 1939; 72: 181-203.
25. Brahme F, Lindström C, Wenckert A. Crohn's disease in a defined population. Gastroenterology 1975; 69: 342-51.
26. Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990; 4: 407-14.
27. Brattsand R, Thalén A, Roempke K, Källström L, Gruvstad E. Development of new glucocorticoids with a very high ratio between topical and systemic activities. Eur J Respir Dis 1982; 63(suppl 122): 62-73.
28. Brignola C, Cottone M, Pera A, Ardizzone S, Scribano ML, De Franchis R et al. Italian cooperative study group: Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology 1995; 108: 345-9.
29. Brignola C, De Simone G, Belloli C, Iannone P, Belluzzi A, Gionchetti P et al. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther 1994; 8: 465-8.
30. Broström O, Löfberg R, Nordenwall B, Öst Å, Hellers G. The risk of colorectal cancer in ulcerative colitis. An epidemilogic study. Scand J Gastroenterol 1987; 22: 1193-9.
31. Calkins BM. A Meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 1841-54.
32. Caprilli R, Andreoli A, Capurso L, Corrao G, D'Albasio GD, Gioieni A et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Aliment Pharmacol Ther 1994; 8: 35-43.
33. Cancer incidence in Denmark 1985. Danish Cancer Society, Copenhagen Danish National Cancer Registry, 1988.
34. Chang SF, Burrell MI, Belleza NA, Spiro HM. Borderlands in the diagnosis of regional enteritis. Gastrointest Radiol 1978; 3: 67-72.
35. Choi PM, Nugent FW, Schoetz DJ, Silverman ML, Haggitt RC. Colonoscopic'surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993; 105: 418-24.
36. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994; 35: 950-4.
37. Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934-44.
38. Comes MC, Gower-Rousseau C, Colombel JF, Belaïche J, Van Kruiningen HJ, Nuttens MC, Cortot A. Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liège county of Belgium. Gut 1994; 35: 1316-8.
39. Crohn B.B., Ginzburg L, Oppenheimer GD. Regional ileitis. JAMA 1932; 99: 1323-9.
40. Cummings JH, Bingham SA, Heaton KW, Eastwood MA. Fecal weight, colon cancer risk, and dietary intake of nonstarch polysaccharides (dietary fiber). Gastroenterology 1992; 103: 1783-9.
41. Dalziel TK. Chronic interstitial enteritis. Br Med J 1913; 2: 1068-70.
42. Delahunty T, Hollander D. New liquid-chromatographic method for measuring polyethylene glycol in urine. Clin Chem 1986; 32: 351-3.
43. Delahunty T, Recher L, Hollander D. Intestinal permeablihty changes in rodents: a possible mechanism for degraded carageenan-induced colitis. Food Chem Toxicol 1987; 25: 113-8.
44. Devlin HB, Datta D, Dellipiani AW. The incidence and prevalence of inflammatory bowel disease in North Tees health district. World J Surg 1980; 4: 183-93.
45. Devroede GJ, Taylor WF, Sauer WG, Jackman RJ, Stickler GB. Cancer risk and life expectancy of children with ulcerative colitis. N Eng J Med 1971; 285: 17-21.
46. Dwarakanath AD, Nash J, Rhodes JM. "Conversion" from ulcerative colitis to Crohn's disease associated with corticosteroid treatment. Gut 1994; 35: 1141-4.
47. Ekbom A, Helmick C, Zack M, Adami H-O. The epidemiology of inflammatory bowel disease: A large, population-based study in Sweden. Gastroenterology 1991; 100: 350-8.
48. Ekbom A, Helmick C, Zack M, Adami H-O. Increased risk of large bowel cancer in Crohn's disease with colonie involvement. Lancet 1990a; 336: 357-9.
49. Ekbom A, Helmick C, Zack M, Adami H-O. Ulcerative colitis and colorectal cancer. New Eng J Med 1990b; 323: 1228-33.
50. Ekbom A, Helmick C, Zack M, Holmberg L, Adami H-O. Survival and causes of death in patients with inflammatory bowel disease. A population-based study. Gastroenterology 1992; 103: 954-60.
51. Ekbom A, Wakefield AJ, Zack M, Adami H-O. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994; 344: 508-10.
52. Ewe K, Herfarth C, Malchow H, Jesdinsky HJ. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: A Multicenter Trial. Digestion 1989; 42: 224-32.
53. Fegan C, Poynton CH, Whittaker JA. The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplantation 1990; 5: 373-7.
54. Fellows IW, Freeman JG, Holmes GKT. Crohn's disease in the city of Derby, 1951-85. Gut 1990; 31: 1262-5.
55. Ferguson A, Sedgwick DM, Drummond J. Morbidity of juvenile onset of inflammatory bowel disease: effects on education and employment in early adult life. Gut 1994; 35: 665-8.
56. Fidler HM, Thurrell W, Johnson N McI, Rook GAW, McFadden JJ. Specific detection of Mycobacterium paratuberculosis DNA associated with granulomatous tissue in Crohn's disease. Gut 1994; 35: 506-10.
57. Fireman Z, Grossman A, Lilos P, Hacohen D, Bar Meir S, Rozen P et al. Intestinal cancer in patients with Crohn's disease. Scand J Gastroenterol 1989; 24: 346-50.
58. Gazzard BG, Price HL, Libby GW, Dawson AM. The social toll of Crohn's disease. Br Med J 1978; 2: 1117-9.
59. Gendre J-P, Mary J-Y, Florent C, Modigliani R, Colombel J-F, Soulé J-C et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study. Gastroenterology 1993; 104: 435-9.
60. Gent AE, Hellier MD, Grace RH, Swarbrick ET, Coggon D. Inflammatory bowel disease and domestic hygiene in infancy. Lancet 1994; 343: 766-7.
61. Gilat T, Grossmann A, Bujanover Y, Rozen P. Epidemiology of inflammatory bowel disease. State of the art and ethiologic interferences. In: Rachmilewitz D, editor, Inflammatory bowel diseases. The Hague: Martinus Nijhoff Publishers, 1982: 143-51.
62. Gilat T, Fireman Z, Grossman A, Hacohen D, Radish U, Ron E et al. Colorectal cancer in patients with ulcerative colitis. A population based study in central Israel. Gastroenterology 1988; 94: 870-7.
63. Gilat T, Hacohen D, Lilos P, Langman JS. Childhood factors in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1987; 22: 1009-24.
64. Gillen CD, Andrews HA, Prior P, Allan RN. Crohn's disease and colorectal cancer. Gut 1994; 35: 651-5.
65. Glotzer DJ. The risk of cancer in Crohn's disease. Gastroenterology 1985; 89: 438-41.
66. Gollop JH, Phillips SF, Melton III LJ, Zinmeister AR. Epidemiologic aspects of Crohn's disease: a population based study in Olmstead County, Minnesota, 1943-1982. Gut 1988; 29: 49-56.
67. Gould SR. Prostaglandins, ulcerative colitis, and sulphasalazine. Lancet 1975; 2: 988.
68. Gower-Rousseau C, Salomez J-L, Dupas J-L, Marti R, Nuttens M-C, Votte A et al. Incidence of inflammatory bowel disease in northern France(1988-1990). Gut 1994; 35: 1433-8.
69. Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson ABR, Williams CN et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331: 836-41.
70. Greenstein AJ, Sachar DB, Smith H, Janowitz HD, Aufses AH. A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer 1981; 48: 2742-5.
71. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci 1988; 33 (suppl): 6S-15S.
72. Gyde SN. Screening for colorectal cancer in ulcerative colitis: dubious benefits and high cost. Gut 1990; 31: 1089-92.
73. Gyde SN, Prior P, Macartney JC, Thompson H, Waterhouse JAH, Allan RN. Malignancy in Crohn's disease. Gut 1980; 21: 1024-9.
74. Halme LEH. Results of surgical treatment of patients with Crohn's disease. Ann Chir Gyn 1992; 81: 277-83.
75. Halme L, von Smitten K, Husa A. The incidence of Crohn's disease in the Helsinki metropolitan area during 1975-1985. Ann Chir Gyn 1989; 78: 115-9.
76. Hamilton SR. Colorectal carcinoma in patients with Crohn's disease. Gastroenterology 1985; 89: 398-407.
77. Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA, and the Pentasa® Crohn's Disease Compassionate Use Study Group. Longterm management of Crohn's disease with mesalamine capsules (Pentasa®). Am J Gastroenterol 1993; 88: 1343-51.
78. Haug K, Schrumpf E, Halvorsen JF, Fluge G, Hamre E, Hamre T, et al. Epidemiology of Crohn's disease in Western Norway. Scand J Gastroenterol 1989; 24: 1271-5.
79. Haug K, Schrumpf E, Barstad S, Fluge G, Halvorsen JF & The study group of inflammatory bowel disease in Western Norway. Epidemiology of ulcerative colitis in Western Norway. Scand J Gastroenterol 1988; 23: 517-22.
80. Hawker PC, Gyde SN, Thompson H, Allan RN. Adenocarcinoma of the small intestine complicating Crohn's disease. Gut 1982; 23: 188-93.
81. Hawkey CJ, Karmeli F, Rachmilewitz D. Imbalance of prostacyclin and tromboxane synthesis in Crohn's disease. Gut 1983; 24: 881-5.
82. Hellers G. Crohn's disease in Stockholm county 1955-74. Acta Chir Scand 1979; (suppl 490): 1-83. (Thesis).
83. Hodgson HJF. One disease or two? In: Inflammatory bowel diseases. Allan RN, Keighley MRB, Alexander-Williams J, Hawkins C, eds. 2nd ed London: Churchill Livingstone, 1990: 121-6.
84. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunthy T, Rotter JI. Increased intestinal permeability in patients with Crohn's disease and their relatives. Ann Intern Med 1986; 105: 883-5.
85. Honn KV, Bockman RS, Marnett LJ. Prostaglandins and cancer: A review of tumor initiation through tumor metastasis. Prostaglandins 1981; 21: 833-63.
86. Isolauri E, Juntunen M, Wiren S, Vuorinen P, Koivula T. Intestinal permeability changes in acute gastroenteritis: effects of clinical factors and nutritional management. J Ped Gastroenterol Nut 1989; 8: 466-73.
87. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Ass 1958; 53: 457-81.
88. Katz KD, Hollander D, Vadheim CM, McElree C, Delahunthy T, Dadufalza VD et al. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 1989; 97: 927-31.
89. Kildebo S, Breckan R, Nordgaard K, Burhol PG, Jorde R & Members of the Northern Norway Gastroenterology Society. The incidence of Crohn's disease in Northern Norway from 1983 to 1986. Scand J Gastroenterol 1989; 24: 1265-70.
90. Kreiner S. Analysis of multidimensional contingency tables by exact conditional tests: techniques and strategies. Scand J Stat 1987; 14: 97-112.
91. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-404.
92. Küster W, Pascoe L, Purrmann J, Funk S, Majewski F. The genetics of Crohn's disease: complex segregation analysis of a family study with 265 patients with Crohn's disease and 5,387 relatives. Am J Med Genet 1989; 32: 105-8.
93. Kyle J. Crohn's disease in the Northeastern and Northern isles of Scotland: An epidemilogical review. Gastroenterology 1992; 103: 392-9.
94. Langevin S, Menard DB, Haddad H, Beaudry R, Poisson J, Devroede G. Idiopathic ulcerative proctitis may be the initial manifestation of Crohn's disease. J Clin Gastroenterol 1992; 15: 199-204.
95. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103: 1444-51.
96. Langholz E, Munkholm P, Haagen Nielsen O, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen County from 1962 to 1987. Scand J Gastroenterol 1991; 26: 1247-56.
97. Lashner BA. Red blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol 1993a; 119: 549-54.
98. Lashner BA. Risk factors of small bowel cancer in Crohn's disease. Dig Dis Sci 1992; 37(8): 1179-84.
99. Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. Gastroenterology 1989; 97: 255-9.
100. Lashner BA, Kane SV, Hanauer SB. Colon cancer surveillance in chronic ulcerative colitis: Historical study. Am J Gastroenterol 1990; 85: 1083-7.
101. Lashner BA, Shaheen NJ, Hanauer SB, Kirschner BS. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol 1993b; 88: 356-9.
102. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leucotriene 84 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91: 837-44.
103. Lee ECG, Papaionnou N. Recurrence following surgery for Crohn's disease. Clinics in Gastroenterology 1980; 9: 419-38.
104. Lee ECG. Aim of surgical treatment of Crohn's diease. Gut 1984; 25: 217-22.
105. Lee FI, Costello FT. Crohn's disease in Blackpool - incidence and prevalence 1968-80. Gut 1985; 26: 274-8.
106. Lennard-Jones JE. Definition and diagnosis. In: Regional enteritis (Crohn's disease). Nordiske Boghandelns Förlag, Stockholm 1971: 105-12.
107. Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990; 31: 800-6.
108. Levine DS, Raisys VA, Ainardi V. Coating of oral beclomethasone diproprionate with cellulose acetate phthalate enhances delivery of topically active drug to the terminal ileum. Gastroenterology 1987; 92: 1037-44.
109. Lindberg E, Järnerot G. The incidence of Crohn's disease is not decreasing in Sweden. Scand J Gastroenterol 1991; 26: 495-500.
110. Lisby G, Andersen J, Engbæk K, Binder V. Mycobacterium paratuberculosis in intestinal tissue from patients with Crohn's disease demonstrated by a nested primer polymerase chain reaction. Scand J Gastroenterol 1994; 29: 923-9.
111. Löfberg R, Rutgeerts P, Malchow H, Lamers C, Olaisson G, Jewell DP et al. Budesonide CIR for maintenance of remission in ileocecal Crohn's disease. A European multicenter placebo controlled trial for 12 months. In: Current research in inflammatory bowel disease. AGA 1994: 89. (Abstract).
112. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H et al. European cooperative Crohn's disease study (ECCDS): Results on drug treatment. Gastroenterology 1984; 86: 249-66.
113. Margulis AR, Goldberg HI, Lawson TL, Montgomery CK, Rambo ON, Noonan CD et al. The overlapping spectrum of ulcerative colitis and granulomatous colitis; a roentgenographic pathologic study. AJR 1971; 113: 325-34.
114. Martinez-Salmeron JF, Rodrigo M, de Teresa J, Nogueras F, García-Montera M, de Sola C et al. Epidemiology of inflammatory bowel disease in the Province of Granada, Spain: a retrospective study from 1979 to 1988. Gut 1993; 34: 1207-9.
115. Maté-Jimenez J, Muñoz S, Vicent D, Pajares JM. Incidence and prevalence of ulcerative colitis and Crohn's disease in urban and rural areas of Spain from 1981 to 1988. J Clin Gastroenterol 1994; 18: 27-31.
116. Maxton DG, Bjarnason I, Reynolds AP, Catt CD, Peters TJ, Menzies IS. Lactulose, 51Cr-labelled ethylenedimine-tetraacetate, L-rhamnose and polyethylene-glycol 400 as probe markers for assessment in vivo of human intestinal permeability. Clin Sci 1986; 71: 71-80.
117. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 1993; 104: 1627-32.
118. Mayberry MK, Probert C, Srivastava E, Rhodes J, Mayberry JF. Preceived discrimination in education and employment by people with Crohn's disease: a case control study of educational achievement and employment. Gut 1992; 33: 312-4.
119. Mayhew JW, Lombardi PE, Fawaz K, Goldin B, Foster EA, Goldberg M et al. Increased oxidation of a chemical carcinogen, benzo(a)pyrene, by colon tissue biopsy specimens from patients with ulcerative colitis. Gastroenterology 1983; 85: 328-34.
120. Mendeloff AI. The epidemiology of chronic inflammatory bowel disease.In: Järnerot G et al, editor, Inflammatory bowel disease Malmö: Corona AB publishers, 1992: 17-33.
121. Mendelsohn RA, Korelitz BI. Crohn's disease presenting as isolated jejunitis years after childhood colitis. Am J Gastroenterol 1993; 88; 105-8.
122. Menzies IS. Transmucosal passage of inert molecules in health and disease. In: Intestinal absorption and secretion editors Skadhauge E, Heintze K. MTP Press Limited 1983: 527-43.
123. Messori A, Brignola C, Trallori G, Rampazzo R, Bardazzi G, Belloli C et al. Effectiveness of 5-Aminosalicylic acid for maintaining remission in patients with Crohn's disease: A meta-analysis. Am J Gastroenterol 1994; 89: 692-8.
124. Meucci G, Vecchi M, Torgano G, Arrigoni M, Prada A, Rocca F et al. Familial aggregation of inflammatory bowel disease in Northern Italy: A multicenter study. Gastroenterology 1992; 103: 514-9.
125. Miller DS, Keighley AC, Langman MJS. Changing patterns in epidemiology of Crohn's disease. Lancet 1974; 2: 691-3.
126. Modigliani R, Mary J-Y, Simon J-F, Cortot A, Soule J-C, Gendre J-P, et al. Clinical, biological and endoscopic picture of attacks of Crohn's disease. Gastroenterology 1990; 98: 811-8.
127. Monsén U, Bernell O, Johansson C, Hellers G. Prevalence of inflammatory bowel disease among relatives of patients with Crohn's disease. Scand J Gastroentrol 1991; 26: 302-6.
128. Moody GA, Mayberry JF. Long-term sulphasalazine protects against colorectal cancer in ulcerative colitis. World Congress of Gastroenterology 1994: 85. (Abstract).
129. Morson BC. Histopathology of Crohn's disease. Proc R Soc Med 1968; 61: 79-81.
130. Mortensen LS, Larsen ME. A data base system for scientific purposes. 1976; 705-7. In: Recent developments in statistics. JR Barra et al editors. North-Holland publishing company 1977.
131. Munkholm Larsen P, Rasmussen D, Rønn B, Elmgren J, Munck O, Binder V. Elemental diet - a therapeutic approach in treatment of ulcerative colitis and Crohn's disease. J Intern Med 1989; 225: 325-31.
132. Müller CF. Letter: Foreningen til bedømmelse af personforsikringsrisiko 1994, 12 Oktober.
133. Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Rønne I. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulphasalazine and 5-aminosalicylic acid. Dig Dis Sci 1987; 32: 577-82.
134. Nordenvall B, Broström O, Berglund M, Monsen U, Nordenström J, Sörstad J et al. Incidence of ulcerative colitis in Stockhom County 1955-79. Scand J Gastroenterol 1985; 20: 783-90.
135. Norlén BJ, Krause U, Bergman L. An epidemiological study of Crohn's disease. Scand J Gastroenterol 1970; 5: 385-90.
136. Nyhlin H, Danielsson Å. Incidence of Crohn's disease in a defined population in Northern Sweden, 1974-81. Scand J Gastroenterol 1986; 21: 1185-92.
137. Ochoa VR. Epidemiology of IBD in Vigo Health area, Spain. Falk Symposium No.76, Spain 5-7.maj 1994: 12-13. (Abstract).
138. Orholm M, Iselius L, Sørensen TIA, Munkholm P, Langholz E, Binder V. Ivestigation of inheritance of chronic inflammatory bowel diseases by complex segregation analysis. Br Med J 1993; 306: 20-4.
139. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TIA, Binder V. Familial occurrence of inflammatory bowel disease. N Eng J Med 1991; 324: 84-8.
140. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 1989; 299: 1247-50.
141. Pennington L, Hamilton SR, Bayless TM, Cameron JL. Surgical management of Crohn's disease: influence of disease at margin of resection. Ann Surg 1980; 192: 311-8.
142. Persson P-G, Karlén P, Bernell O, Leijonmarck C-E, Broström O, Ahlbom A et al. Crohn's disease and cancer: A population-based cohort study. Gastroenterology 1994; 107: 1675-9.
143. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami H-O. Risk factors for colorectal cancer in patients with ulcerative colitis: A case control study. Gastroenterology 1994; 107: 117-20.
144. Pironi L, Miglioli M, Ruggeri E, Dallsata M.A, Ornigotti L, Valpiani D et al. Effect of non-steroidal anti-inflammatory drugs (NSAID) on intestinal permeability in first degree relatives of patients with Crohn's disease. Gastroenterology 1992; 102/4(part 2): A697. (Abstract).
145. Polon ATR. Cancer surveillance in ulcerative colitis: a time for reappraisal. Gut 1994; 35: 587-9.
146. Prantera C, Pallone F, Brunetti G, Cottone M, Miglioli M and The Italian IBD study group. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103: 363-8.
147. Prior P, Gyde S, Cooke WT, Waterhouse JAH, Allan RN. Mortality in Crohn's disease. Gastroenterology 1981; 80: 307-12.
148. Probert CSJ, Jayanthi V, Wicks ACB, Mayberry JF. Mortality from Crohn's disease in Leicestershire, 1972-1989: an epidemiological community based study. Gut 1992; 33: 1226-8.
149. Prytz H, Benoni C, Tageson C. Does smooking tighten the gut? Scand J Gastroenterol 1989; 24: 1084-8.
150. Rachmilewitz D, Ligumsky M, Haimovitz A, Treves AJ. Prostanoid synthesis by cultered peripheral blood mononuclear cells in inflammatory diseases of the bowel. Gastroenterology 1982; 82: 673-9.
151. Rampton DS, Hawkey CJ. Prostaglandins and ulcerative colitis. Gut 1984; 25: 1399-1413.
152. Ranzi T, Campinini MC, Lisciandrano D, Bodini P, Polin P, Zambelli A et al. Incidence of IBD in North Italy: A four year prospective study (1990-1993). World Congresses of Gastroenterology, Los Angeles 2-7. October 1994: 531p. (Abstract).
153. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nosteroidal anti-inflammatory drug with D, L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990; 50: 2562-8.
154. Richards ME, Rickert RR, Nance FC. Crohn's disease-associated carcinoma. A poorly recognized complication of inflammatory bowel disease. Ann Surg 1989; 209: 764-73.
155. Riis P, Anthonisen P. The differential diagnosis between ulcerative colitis and Crohn's disease in the colon. Ugeskr Læg 1969; 131: 6-9.
156. Roberts RS, Spitzer WO, Delmore T, Sackett DL. An emperical demonstration of Berkson's bias. J Chron Dis 1978; 31: 119-28.
157. Rose JDR, Roberts GM, Williams G, Mayberry JF, Rhodes J. Cardiff Crohn's disease jubilee: The incidence over 50 years: Gut 1988; 29: 346-51.
158. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Samuel S. A Hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991; 83: 355-8.
159. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-63.
160. Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewel DP et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5.
161. Ruttenberg D, Young GO, Wright JP, Isaacs S. PEG-400 excretion in patients with Crohn's disease, their first-degree relatives, and healthy volunteers. Dig Dis Sci 1992; 37: 705-8.
162. Sackett DL, Whelan G. Cancer risk in ulcerative colitis: Scientific requirements for the study of prognosis. Gastroenterology 1980; 78; 1632-4.
163. Sachar DB. Clinical and colonoscopic surveillance in ulcerative colitis: Are we saving colons or saving lives? Gastroenterology 1993; 105: 588-9.
164. Sachar DB. The new steroids: Can there be potency without toxicity? Mt Sinai J Med 1990; 57: 289-91.
165. Sachar DB, Wolfson DM, Greenstein AJ, Goldberg J, Styczynski R, Janowitz HD. Risk factors for postoperative recurrence of Crohn's disease. Gastroenterology 1983; 85: 917-21.
166. Sanderson R, Boulton P, Menzies IS, Walker-Smith JA. Improvement of abnormal lactulose/rhamnose permeability in active Crohn's disease of the small bowel by an elemental diet. Gut 1987; 28: 1073-6.
167. Sanderson JD, Moss MT, Tizard MLV, Hermon-Taylor J. Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Gut 1992; 33: 890-6.
168. Sawyerr AM, Ferguson A. Ulcerative colitis and Crohn's disease: similarities and distinctions. J R Coll Physicians Lond 1994; 28: 197-9.
169. Seldenrijk CA, Morson BC, Meuwissen SGM, Schipper NW, Lindeman J, Meijer CJLM. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut 1991; 32: 1514-20.
170. Shivananda S. European Community initiative on inflammatory bowel disease. The Lancet 1988; II; 1321.
171. Shivananda S, Hordijk ML, Peña AS, Mayberry JF. Inflammatory bowel disease: One condition or two? Digestion 1987a; 38: 187-92.
172. Shivananda S, Peña AS, Mayberry JF, Ruttenberg EJ, Hoedemaeker PJ. Epidemiology of proctocolitis in the region of Leiden, The Netherlands. Scand J Gastroenterol 1987b; 22: 993-1002.
173. Shivananda S, Peña AS, Nap M, Weterman IT, Mayberry JF, Ruitenberg EJ et al. Epidemiology of Crohn's disease in region of Leiden, the Netherlands. Gastroenterology 1987c; 93: 966-74.
174. Singleton JW, Law DH, Kelley ML, Mekhjian HS, Sturdevant RAL. National Cooperative Crohn's disease study: reverse reactions to study drugs. Gastroenterology 1979; 77: 870-82.
175. Smart H, Mayberry J, Calcraft B, Morris JS, Rhodes J. Effect of informationbooklets on patients' anxiety levels and consultaion rates in Crohn's disease. Publ Health 1986; 100: 184-6.
176. Smith IS, Young S, Gillespie G, O'Connor J, Bell JR. Epidemiological aspects of Crohn's disease in Clydesdale 1961-70. Gut 1975; 16: 62-7.
177. Sonnenberg A. Disability from inflammatory bowel disease among employees in West Germany. Gut 1989; 30: 367-70.
178. Statistical table works. Copenhagen: Danmarks Statistik, 1962-87.
179. Stonnington CM, Phillips SF, Zinmeister AR, Melton LJ III. Prognosis of chronic ulcerative colitis in a community. Gut 1987; 28: 1261-6.
180. Summers RW, Switz DM, Sessions JT, Becktel JM, Best WR, Kern F et al. National Cooperative Crohn's disease study: Results of drug treatment. Gastroenterology 1979; 77: 847-69.
181. Sørensen VZ, Olsen BG, Binder V. Life prospects and quality of life in patients with Crohn's disease. Gut 1987; 28: 382-5.
182. Tan WC, Allan RN. Diffuse jejunoileitis of Crohn's disease. Gut 1993; 34: 1374-8.
183. Tanaka K, Wilks M, Coates PJ, Farthing MJG, Walker-Smith JA, Tabaqchali S. Mycobacterium paratuberculosis and Crohn's disease. Gut 1991; 32: 43-5.
184. Theahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in patients with Crohn's disease and their first degree relatives. Gut 1992; 33: 320-3.
185. Theodossi A, Spiegelhalter DJ, Jass J, Firth J, Dixon M, Leader M et al. Observer variation and discriminatory value of biopsy features in inflammatory bowel disease. Gut 1994; 35: 961-8.
186. Thomson BR and international mesalazine study group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Therap 1990; 4: 55-64.
187. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Eng J Med 1991; 325: 1593-6.
188. Tragnone A, Hanau C, Bazzocchi G, Lanfranchi GA. Epidemiological characteristics of inflammatory bowel disease in Bologna, Italy - Incidence and risk factors. Digestion 1993; 54: 183-8.
189. Trallori G, d'Albasio G, Palli D, Bardazzi G, Cipriani F, Fritelli G et al. Epidemiology of inflammatory bowel disease over a 10-year period in Florence(1978-1987). Ital J Gastroenterol 1991; 23: 559-63.
190. Truelove SC, Peña AS. Course and prognosis of Crohn's disease. Gut 1976; 17: 192-201.
191. Tsianos EV, Masalas CN, Merkouropoulos M, Dalekos GN, Logan RFA. Incidence of inflammatory bowel disease in north west Greece: rarity of Crohn's disease in an area where ulcerative colitis is common. Gut 1994; 35: 369-72.
192. Tytgat GNJ, Mulder CJJ, Brummelkamp WH. Endoscopic lesions in Crohn's disease early after ilececal resection. Endoscopy 1988; 20: 260-2.
193. Van Kruiningen HJ, Colombel JF, Cartun RW, Whitlock RH, Koopmans M, Kangro HO et al. An in-depth study of Crohn's disease in two French families. Gastroenterology 1993; 104: 351-60.
194. Veloso FT, Goncalves R, Noronha R, Barata J, Lima M, Machado C et al. Incidence of inflammatory bowel disease in the district of Braga (Northwest Portugal). Falk Symposium No.76, Spain 5-7.maj 1994: 39. (Abstract).
195. Wakefield AJ, Pittilo RM, Sim R, Cosby SL, Stephenson JR, Dhillon AP et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Vir 1993; 39: 345-53.
196. Weedon DD, Shorter RG, Duane M, Ilstrup MS, Huizenga KA, Taylor WF. Crohn's disease and cancer. N Eng J Med 1973; 289: 1099-1103.
197. Wells C. Ulcerative colitis and Crohn's disease. Ann Royal Coll Surg Engl 1952; 11: 105-20.
198. Weterman IT, Biemond I, Peña AS. Mortality and causes of death in Crohn's disease. Review of 50 years' experience in Leiden University Hospital. Gut 1990; 31: 1387-90.
199. Whittaker J. Graphical models in applied Multivariate Analysis. New York. Wiley 1990.
200. Wright JP. Factors influencing first relapse in patients with Crohn's disease. J Clin Gastroenterol 1992; 15(1): 12-6.
201. Wyatt J, Vogelsang H, Lochs H. Effect of corticosteroids on intestinal permeability in patients with active Crohn's disease. Gastroenterology 1992; 102/4 (part 2): A947. (Abstract).
202. Wyatt J, Vogelsang H, Hübl W, Waldhöer T, Lochs H. Intestinal permeability and the prediction of relapse of Crohn's disease. Lancet 1993; 341: 1437-9.
203. Øktedalen O, Lunde OC, Opstad PK, Aabakken L, Kvernebo K. Changes in the gastrointestinal mucosa after long-distance running. Scand J Gastroenterol 1992; 27: 270-4.